The macrolide antibiotics global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Macrolide Antibiotics Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The macrolide antibiotics market size has grown rapidly in recent years. It will grow from $52.98 billion in 2023 to $59.07 billion in 2024 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing antibiotic resistance, approvals for new formulations, a rise in infectious diseases, and government and healthcare initiatives.
The macrolide antibiotics market size is expected to see rapid growth in the next few years. It will grow to $91.64 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to a rise in respiratory infections due to factors like arise in respiratory infections, rise in combination therapies, an increase in the global geriatric population, increased awareness and diagnostics, and growth in telemedicine and online pharmacy services. Major trends in the forecast period include advancements in drug delivery systems and formulations, the development of novel macrolide antibiotics, advancements in telemedicine and remote healthcare services, and the development of eco-friendly manufacturing processes for macrolide antibiotics.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/macrolide-antibiotics-global-market-report
Scope Of Macrolide Antibiotics Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Macrolide Antibiotics Market Overview
Market Drivers –
The increasing prevalence of skin infections is expected to propel the growth of the macrolide antibiotics market going forward. A skin infection is a condition caused by the invasion of harmful microorganisms into the skin, leading to inflammation and often accompanied by symptoms such as redness, swelling, and pain. Growing skin infections may result from factors such as poor hygiene practices, compromised immune systems, exposure to environmental pollutants, antibiotic resistance, and inadequate wound care. Macrolide antibiotics are often prescribed for treating skin infections caused by bacteria such as Staphylococcus aureus or Streptococcus pyogenes, particularly in cases of penicillin allergy or resistance. For instance, in September 2022, according to the UK Health Security Agency (UKHSA), a UK-based national executive agency, the percentage of Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia cases attributed to skin and soft tissue infections rose from 25.7% in the financial year April 2020 to March 2021 to 33.7% in the financial year April 2021 to March 2022. Similarly, for Methicillin-Sensitive Staphylococcus aureus (MSSA) bacteremia cases, the percentage increased from 27.2% to 28.5% over the same period. Therefore, the increasing prevalence of skin infections is driving the growth of the macrolide antibiotics market.
Market Trends –
Major companies operating in the macrolide antibiotic market are focusing on developing generic formulations to increase accessibility, reduce treatment costs, and expand their market reach. Generic formulations of macrolide antibiotics are non-branded versions of these drugs that contain the same active ingredients, dosage, and strength as the original branded medications. For instance, in May 2021, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, launched its generic version of Erythromycin Tablets USP in the United States. This generic medication is used to treat or prevent a range of bacterial infections, including respiratory tract infections, skin infections, and infections of the ear, nose, and throat. Erythromycin is a macrolide antibiotic that works by inhibiting the growth of bacteria, thereby helping to alleviate symptoms and prevent the spread of infection. The generic version of Erythromycin Tablets USP is available in various strengths, including 250 mg and 500 mg, and is expected to provide patients with a more affordable treatment option for their bacterial infections.
The macrolide antibiotics market covered in this report is segmented –
1) By Drugs: Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, Telithromycin
2) By Indication: Respiratory Tract Infections, Skin Infections, Sexually Transmitted Infections, Gastrointestinal Infections, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
4) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
5) By End User: Hospital, Dermatology Clinic, Clinic, Ambulatory Centre, Research Laboratories
Get an inside scoop of the macrolide antibiotics market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16472&type=smp
Regional Insights –
North America was the largest region in the macrolide antibiotics market in 2023. The regions covered in the macrolide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the macrolide antibiotics market are <b>Pfizer Inc., Roche Holding AG, Merck Sharp & Dohme Corp, AbbVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc., Eli Lily and Company, Amgen Inc., Teva Pharmaceutical Industries Limited, Mylan N.V., Daiichi Sankyō, Sun Pharmaceutical Industries Limited, Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Zhejiang Guobang Pharmaceutical Co. Ltd., Fresenius Kabi USA, WOCKHARDT, Crescent Pharma Limited, Wellona Pharma Private Limited </b>
Table of Contents
1. Executive Summary
2. Macrolide Antibiotics Market characterstics
3. Macrolide Antibiotics Market Trends And Strategies
4. Macrolide Antibiotics Market – Macro Economic Scenario
5. Global Macrolide Antibiotics Market Size And Growth
…..
32. Global Macrolide Antibiotics Market Competitive Benchmarking
33. Global Macrolide Antibiotics Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Macrolide Antibiotics Market
35. Macrolide Antibiotics Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
